Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2017-10-26 Earnings Release
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
Earnings Release 2017
Earnings Release Classification · 99% confidence The document is explicitly titled 'BioInvent Interim Report' and covers the period '1 January – 30 September 2017', detailing financial results for the third quarter and the nine-month period. This structure—a comprehensive financial report for a period shorter than a full year—perfectly matches the definition of an Interim/Quarterly Report. The code for this is 'IR'. The document is substantial and contains detailed financial figures, not just an announcement of a report, thus ruling out RPA or RNS based on the 'MENU VS MEAL' rule. 9M 2017
2017-10-26 English
The CEO of BioInvent Michael Oredsson will resign at the end of the year
Board/Management Information Classification · 98% confidence The document explicitly announces the resignation of the CEO, Michael Oredsson, effective December 31, 2017. This type of announcement concerns a change in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is a direct announcement of this change, not a general regulatory filing (RNS) or a report itself.
2017-10-24 English
BioInvents VD Michael Oredsson avgår vid årsskiftet
Board/Management Information Classification · 98% confidence The document is a press release from BioInvent International AB announcing the resignation of its CEO, Michael Oredsson, effective at the end of the year. It details the reasons for the change (transitioning focus to R&D requiring more scientific expertise in the CEO role) and names the interim successor. This type of announcement, concerning changes in senior management or the board of directors, directly corresponds to the definition for Board/Management Information (MANG). The document length is short (3163 chars), but it is a primary announcement, not an announcement *of* another report, so RPA/RNS is less appropriate than the specific MANG category.
2017-10-24 Swedish
Det japanska patentverket avser bevilja BioInvents viktiga patent relaterat till den immunonkologiska antikroppen BI-1206
Regulatory Filings Classification · 95% confidence The document is a press release dated September 12, 2017, announcing that the Japanese Patent Office intends to grant a patent related to the oncology antibody BI-1206. It details the scope of the patent and mentions that this is the third patent granted in this family. The text concludes with a statement that this information is subject to disclosure under the EU Market Abuse Regulation (MAR) and specifies the time of release. This type of announcement, which is a specific corporate update (patent grant decision) released via a press release format, does not fit the definitions for formal financial reports (10-K, IR, ER) or specific corporate actions like dividends or management changes. Since it is a specific regulatory/corporate announcement that doesn't fit the highly specific categories like DIRS, DIV, or CAP, the most appropriate general category for significant, non-financial regulatory updates that are not standard reports is 'Regulatory Filings' (RNS). It is not an announcement of a report publication (RPA), but the news itself.
2017-09-12 Swedish
The Japanese patent office intends to grant BioInvent’s important patent relating to the immune-oncology antibody BI-1206
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE" dated September 12, 2017. It announces a specific corporate event: the Japanese patent office's intention to grant a patent for the antibody BI-1206. This type of announcement, detailing progress in intellectual property or clinical trials, is generally classified as a general regulatory announcement or news release that doesn't fit the strict definitions of 10-K, ER, or IR. Since it is a specific, non-financial regulatory update (patent news) and not a standard financial report, it falls best under the general 'Regulatory Filings' category (RNS) as a catch-all for important, non-standard announcements, or potentially 'LTR' if patent litigation was involved, but here it is positive news. Given the options, RNS is the most appropriate fallback for a general press release about IP progress.
2017-09-12 English
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is a 'delårsrapport' (interim report) for BioInvent covering the period from January 1 to June 30, 2017. It contains detailed financial statements, including income statements, cash flow analysis, and balance sheet data, as well as management commentary on business operations and pipeline developments. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2017
2017-07-26 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.